Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lansoprazole Clear all
Completed Phase 1Phase 2 Interventional Results available

Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain

NCT00685295
View directory record Official record
Conditions
Pain, Fracture, Sprain
Interventions
Fentanyl, Lansoprazole, Oxycodone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Infected Blood Dendritic Cells in Heart Disease Risk

NCT01568944
View directory record Official record
Conditions
Chronic Periodontitis
Interventions
Oral Antibiotic and Oral Rinse, Standard Treatment
Drug · Procedure
Lead sponsor
Augusta University
Other
Eligibility
40 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Proton Pump Inhibitors on Endothelial Function

NCT02022280
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Lansoprazole, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Not applicable Interventional Results available

Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis

NCT00880906
View directory record Official record
Conditions
Suspected Eosinophilic Esophagitis
Interventions
Esophageal dilation, Steroid and Proton Pump Inhibitor Therapy
Procedure · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lansoprazole 30 mg DR Capsule Replicate Food Study

NCT01046084
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Prevacid®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 25, 2026, 6:34 AM EDT
Terminated Phase 4 Interventional Results available

Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness

NCT00637416
View directory record Official record
Conditions
Dysphonia
Interventions
Lansoprazole, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
3 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants

NCT02064907
View directory record Official record
Conditions
Bioavailability
Interventions
Dexlansoprazole Delayed Release Orally Disintegrating Tablets, Dexlansoprazole Delayed Release Capsules
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 25, 2026, 6:34 AM EDT
Terminated Phase 2 Interventional

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

NCT02615184
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Mobile, Alabama • San Francisco, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn

NCT00701259
View directory record Official record
Conditions
Frequent Heartburn
Interventions
Lansoprazole, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects

NCT00952913
View directory record Official record
Conditions
Healthy
Interventions
Bosutinib, Lansoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251745
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 4 Interventional

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

NCT00295685
View directory record Official record
Conditions
GERD
Interventions
Antacids
Drug
Lead sponsor
Digestive & Liver Disease Specialists
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2009 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury

NCT01270659
View directory record Official record
Conditions
Pain
Interventions
Fentanyl, oxycodone/acetaminophen
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Not applicable Interventional

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

NCT00573924
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Proton pump inhibitor (lansoprazole)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Sep 25, 2026, 6:34 AM EDT
Terminated No phase listed Observational

Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

NCT00624546
View directory record Official record
Conditions
GERD, Gastroesophageal Reflux
Interventions
Prevacid Solutabs, Antireflux surgery
Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Sep 25, 2026, 6:34 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Reducing Stomach Acid on Post-tonsillectomy Pain

NCT00472186
View directory record Official record
Conditions
Post-tonsillectomy Pain, Post-tonsillectomy Activity, Post-tonsillectomy Hydration
Interventions
Lansoprazole, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 25, 2026, 6:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

NCT03059303
View directory record Official record
Conditions
Healthy
Interventions
Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

NCT01155284
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sitagliptin and Lansoprazole, Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
11 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

NCT03801148
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 2 Interventional Results available

Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis

NCT00638456
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Budesonide plus Prevacid, placebo plus Prevacid
Drug
Lead sponsor
Ranjan Dohil
Other
Eligibility
1 Year and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 25, 2026, 6:34 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux

NCT01317472
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
dexlansoprazole, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 25, 2026, 6:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00321737
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
80
States / cities
Huntsville, Alabama • Tuscon, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 25, 2026, 6:34 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparison of Voice Therapy and Antireflex Therapy in LPR

NCT02530879
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Omeprazole, Lansoprazole, Esomeprazole, Rantidine, Voice therapy, Combination of anti-reflux medication and voice therapy
Drug · Behavioral · Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 25, 2026, 6:34 AM EDT